How Many mg Is 20 Units of Tirzepatide?

Why does tirzepatide use units at all, and where does the 0.25 mg figure come from?

Tirzepatide solutions are formulated at a concentration of 0.25 mg per unit (equivalent to 2.5 mg per mL). The Mounjaro KwikPen dials in whole units, which is a common engineering choice for injection devices, it keeps the mechanism precise and the markings legible. The milligram figure is what appears in prescriptions, clinical trial reports, and the official Summary of Product Characteristics.

Because the concentration is fixed across every Mounjaro pen strength, the conversion is always linear: multiply the unit count by 0.25 to get milligrams. Twenty units sits squarely at 5 mg. You can check the full breakdown of the 5 mg Mounjaro pen, which corresponds to this dose, on our treatment information page.

The NHS tirzepatide medicines page confirms the concentration and describes the six UK strengths available in the pre-filled pen format, which is worth reading alongside any dose query: NHS information on tirzepatide.

Quick sanity-check: keep your pen in the fridge door between weekly doses, and each time you dial up, the unit readout and the milligram dose on your prescription should match exactly using this factor.

What are 20 units of tirzepatide actually used for in the licensed dose schedule?

Five milligrams (20 units) is the second rung of the standard Mounjaro titration pathway. Treatment begins at 2.5 mg for the first four weeks, a starting dose whose job is to let your system adjust rather than to drive significant weight change. After that initial period, a prescriber typically increases the dose to 5 mg, where patients stay for at least another four weeks before any further step.

So 20 units is very much an active therapeutic dose, not a transitional one. Many people find their tolerability improves meaningfully at this stage. For context on what the earlier step involves in unit terms, the page on how many units is 2.5 mg of tirzepatide covers the 10-unit starting dose in detail.

The titration continues in 4-week steps (7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg) each step decided by the prescriber based on tolerability and progress, not a fixed calendar. NICE's appraisal of tirzepatide (NICE TA1026) covers the clinical evidence supporting this escalation approach for adults with obesity.

The maximum licensed UK dose is 15 mg (60 units). If you want to see how 20 units compares to higher doses, the page on 30 units of tirzepatide covers the 7.5 mg step.

Can I use units to figure out when to increase my dose?

No, and this is the part worth stating plainly. The maths of converting units to milligrams is straightforward, but the question of whether to increase, when to increase, and to which dose is entirely clinical. It depends on how you've tolerated the current dose, your weight trajectory, any side effects you've reported, and your prescriber's overall assessment.

Some people stay at 5 mg (20 units) for longer than four weeks if tolerability needs more time. Others move through the schedule faster if circumstances allow. The Mounjaro treatment overview explains the broader clinical picture, and our frequently asked questions page covers the most common dose-timing queries our team receives.

A related conversion that catches people out: how many units is 5 mg of tirzepatide answers the same question from the opposite direction, which can be useful if your prescription states milligrams and your pen shows units.

If you're researching tirzepatide as a potential treatment and want to understand costs before starting, our Mounjaro price comparison page sets out what private treatment typically involves in the UK.

What about side effects at this dose, and when should you contact someone?

Five milligrams is where a meaningful number of patients notice GI effects for the first time, or find that effects which were mild at 2.5 mg become more noticeable. Loose stools, nausea, a reduced appetite and occasional reflux are the most commonly reported. These usually settle within one to two weeks of starting or stepping up.

Staying hydrated matters more than it sounds. Prolonged nausea or vomiting can lead to dehydration quickly, and that can have knock-on effects on kidney function. Contact your prescriber or GP promptly if you can't keep fluids down for more than 24 hours, or if you develop severe, persistent stomach pain that spreads toward the back, that's the pattern associated with acute pancreatitis, which the MHRA flagged in early 2026 as a known but infrequent risk with GLP-1 medicines. You can report any suspected side effect via the MHRA Yellow Card scheme.

More routine questions about how the medicine is going (tolerability, whether a dose change feels right, anything that's making you uncertain) are exactly what aftercare is for. Our contact page explains how to reach our clinical team any day of the week.